Recent advances in the discovery of selective AMPA receptor positive allosteric modulators

Current Medicinal Chemistry

Volumn 17, Issue 30, 2010, Pages 3503-3513

  Ward, Simon E ^a   Harries, Mark ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Ampa positive modulator; Ampa receptor

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR AGONIST; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; TRIAZINE DERIVATIVE;

ARTICLE; CHEMICAL ANALYSIS; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS;

ALLOSTERIC REGULATION; BENZAMIDES; DRUG EVALUATION, PRECLINICAL; PYRAZOLES; PYRROLES; RECEPTORS, AMPA; SULFONAMIDES; THIAZOLES; THIOPHENES;

EID: 77957947835     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710792927840     Document Type: Article

References (75)

1. Sanacora, G.; Zarate, C. A.; Krystal, J. H.; Manji, H. K. Targetingthe glutamatergic system to develop novel, improved therapeuticsfor mood disorders. Nat. Rev. Drug Discov., 2008, 7, 426-437.
2. Zarate, C. A. Jr.; Manji, H. K. The role of AMPA receptor modula-tion in the treatment of neuropsychiatric diseases. Exp. Neurol.,2008, 211, 7-10.
3. Black, M. D. Therapeutic potential of positive AMPA modulatorsand their relationship to AMPA receptor subunits. A review of pre-clinical data. Psychopharmacology (Berl), 2005, 179, 154-163.
4. Granger, R.; Staubli, U.; Davis, M.; Perez, Y.; Nilsson, L.; Rogers, G. A.; Lynch, G. A drug that facilitates glutamatergic transmissionreduces exploratory activity and improves performance in a learn-ing-dependent task. Synapse, 1993, 15, 326-329.
5. Lynch, G.; Gall, C. M. Ampakines and the threefold path to cogni-tive enhancement. Trends Neurosci., 2006, 29, 554-562.
6. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S. F. The gluta-mate receptor ion channels. Pharmacol. Rev., 1999, 51, 7-61.
7. Ozawa, S.; Kamiya, H.; Tsuzuki, K. Glutamate receptors in themammalian central nervous system. Prog. Neurobiol., 1998, 54,581-618.
8. Malenka, R. C. Synaptic plasticity and AMPA receptor trafficking.Ann. N. Y. Acad. Sci., 2003, 1003, 1-11.
9. Mansour, M.; Nagarajan, N.; Nehring, R. B.; Clements, J. D.;Rosenmund, C. Heteromeric AMPA receptors assemble with a pre-ferred subunit stoichiometry and spatial arrangement. Neuron,2001, 32, 841-853.
10. Tichelaar, W.; Safferling, M.; Keinanen, K.; Stark, H.; Madden, D.R. The three-dimensional structure of an ionotropic glutamate re-ceptor reveals a dimer-of-dimers assembly. J. Mol. Biol., 2004,344, 435-442.
11. Seeburg, P. H.; Single, F.; Kuner, T.; Higuchi, M.; Sprengel, R.Genetic manipulation of key determinants of ion flow in glutamatereceptor channels in the mouse. Brain Res., 2001, 907, 233-243.
12. Armstrong, N.; Gouaux, E. Mechanisms for activation and antago-nism of an AMPA-sensitive glutamate receptor: crystal structuresof the GluR2 ligand binding core. Neuron, 2000, 28, 165-181.
13. Gouaux, E. Structure and function of AMPA receptors. J. Physiol.,2004, 554, 249-253.
14. Collingridge, G. L.; Isaac, J. T.; Wang, Y. T. Receptor traffickingand synaptic plasticity. Nat. Rev. Neurosci., 2004, 5, 952-962.
15. Milstein, A. D.; Nicoll, R. A. Regulation of AMPA receptor gatingand pharmacology by TARP auxiliary subunits. Trends Pharmacol.Sci., 2008, 29, 333-339.
16. Tomita, S.; Adesnik, H.; Sekiguchi, M.; Zhang, W.; Wada, K.; Howe, J. R.; Nicoll, R. A.; Bredt, D. S. Stargazin modulates AMPAreceptor gating and trafficking by distinct domains. Nature, 2005,435, 1052-1058.
17. Soto D.; Coombs I. D.; Kelly L.; Farrant M.; Cull-Candy S. G.Stargazin attenuates intracellular polyamine block of calcium-permeable AMPA receptors. Nat. Neurosci., 2007, 10, 1260-1267.
18. Sommer, B.; Keinanen, K.; Verdoorn, T. A.; Wisden, W.; Bur-nashev, N.; Herb, A.; Kohler, M.; Takagi, T.; Sakmann, B.; See-burg, P. H. Flip and flop: a cell-specific functional switch in gluta-mate-operated channels of the CNS. Science, 1990, 249, 1580-1585.
19. Leever, J. D.; Clark, S.; Weeks, A. M.; Partin, K. M. Identificationof a site in GluR1 and GluR2 that is important for modulation ofdeactivation and desensitization. Mol. Pharmacol., 2003, 64, 5-10.
20. Harpsoe, K.; Liljefors, T.; Balle, T. Prediction of the binding modeof biarylpropylsulfonamide allosteric AMPA receptor modulatorsbased on docking, GRID molecular interaction fields and 3D-QSAR analysis. J. Mol. Graph. Model, 2008, 26, 874-883.
21. Ptak, C. P.; Ahmed, A. H.; Oswald, R. E. Probing the allostericmodulator binding site of GluR2 with thiazide derivatives. Bio-chemistry, 2009, 48, 8594-8602.
22. Jin, R.; Clark, S.; Weeks, A. M.; Dudman, J. T.; Gouaux, E.; Partin, K. M. Mechanism of positive allosteric modulators actingon AMPA receptors. J. Neurosci., 2005, 25, 9027-9036.
23. O'Neill, M. J.; Bleakman, D.; Zimmerman, D. M.; Nisenbaum, E.S. AMPA receptor potentiators for the treatment of CNS disorders.Curr. Drug Targets CNS Neurol. Disord., 2004, 3, 181-194.
24. Quirk, J. C.; Nisenbaum, E. S. LY404187: a novel positive allos-teric modulator of AMPA receptors. CNS Drug Rev., 2002, 8, 255-282.
25. Kim, K. S.; Yan, D.; Tomita, S. Assembly and stoichiometry of theAMPA receptor and transmembrane AMPA receptor regulatoryprotein complex. J. Neurosci., 2010, 30, 1064-1072.
26. Sumioka, A.; Yan, D.; Tomita, S. TARP phosphorylation regulatessynaptic AMPA receptors through lipid bilayers. Neuron, 2010, 66,755-767.
27. Schwenk, J.; Harmel, N.; Zolles, G.; Bildl, W.; Kulik, A.; Heim-rich, B.; Chisaka, O.; Jonas, P.; Schulte, U.; Fakler, B.; Klocker, N.Functional proteomics identify cornichon proteins as auxiliarysubunits of AMPA receptors. Science, 2009, 323, 1313-1319.
28. Tigaret, C.; Choquet, D. Neuroscience. More AMPAR garnish.Science, 2009, 323, 1295-1296.
29. Farrant, M.; Cull-Candy, S. G. Neuroscience. AMPA receptors--another twist? Science, 2010, 327, 1463-1465.
30. von, E. J.; Mack, V.; Sprengel, R.; Kavenstock, N.; Li, K. W.; Stern-Bach, Y.; Smit, A. B.; Seeburg, P. H.; Monyer, H. CKAMP44: a brain-specific protein attenuating short-term synapticplasticity in the dentate gyrus. Science, 2010, 327, 1518-1522.
31. Fleming, J. J.; England, P. M. Developing a complete pharmacol-ogy for AMPA receptors: a perspective on subtype-selectiveligands. Bioorg. Med. Chem., 2010, 18, 1381-1387.
32. Emond, M. R.; Montgomery, J. M.; Huggins, M. L.; Hanson, J. E.;Mao, L.; Huganir, R. L.; Madison, D. V. AMPA receptor subunitsdefine properties of state-dependent synaptic plasticity. J Physiol,2010, 588, 1929-1946.
33. Arai, A.; Guidotti, A.; Costa, E.; Lynch, G. Effect of the AMPAreceptor modulator IDRA 21 on LTP in hippocampal slices.Neuroreport, 1996, 7, 2211-2215.
34. Arai, A. C.; Xia, Y. F.; Suzuki, E. Modulation of AMPA receptorkinetics differentially influences synaptic plasticity in the hippo-campus. Neuroscience, 2004, 123, 1011-1024.
35. Lynch, G. Memory enhancement: the search for mechanism-baseddrugs. Nat. Neurosci., 2002, 5 Suppl, 1035-1038.
36. Hampson, R. E.; Rogers, G.; Lynch, G.; Deadwyler, S. A. Facilita-tive effects of the ampakine CX516 on short-term memory in rats:correlations with hippocampal neuronal activity. J. Neurosci.,1998, 18, 2748-2763.
37. Lebrun, C.; Pilliere, E.; Lestage, P. Effects of S 18986-1, a novelcognitive enhancer, on memory performances in an object recogni-tion task in rats. Eur. J. Pharmacol., 2000, 401, 205-212.
38. Woolley, M. L.; Waters, K. A.; Gartlon, J. E.; Lacroix, L. P.; Jennings, C.; Shaughnessy, F.; Ong, A.; Pemberton, D. J.; Harries, M. H.; Southam, E.; Jones, D. N.; Dawson, L. A. Evaluation of thepro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.Psychopharmacology (Berl), 2009, 202, 343-354.
39. Zivkovic, I.; Thompson, D. M.; Bertolino, M.; Uzunov, D.; DiBella, M.; Costa, E.; Guidotti, A. 7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a ben-zothiadiazine derivative that enhances cognition by attenuating DL-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoicacid (AMPA) receptor desensitization. J. Pharmacol. Exp. Ther.,1995, 272, 300-309.
40. Buccafusco, J. J.; Weiser, T.; Winter, K.; Klinder, K.; Terry, A. V.The effects of IDRA 21, a positive modulator of the AMPA recep-tor, on delayed matching performance by young and aged rhesusmonkeys. Neuropharmacology, 2004, 46, 10-22.
41. Porrino, L. J.; Daunais, J. B.; Rogers, G. A.; Hampson, R. E.;Deadwyler, S. A. Facilitation of task performance and removal ofthe effects of sleep deprivation by an ampakine (CX717) in non-human primates. PLoS Biol., 2005, 3, e299.
42. Thompson, D. M.; Guidotti, A.; DiBella, M.; Costa, E. 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA21), a congener of aniracetam, potently abates pharmacologicallyinduced cognitive impairments in patas monkeys. Proc. Natl. Acad.Sci. U. S. A, 1995, 92, 7667-7671.
43. Francotte, P.; de, Tullio, P.; Fraikin, P.; Counerotte, S.; Goffin, E.;Pirotte, B. In search of novel AMPA potentiators. Recent Pat CNSDrug Discov., 2006, 1, 239-246.
44. Morrow, J. A.; Maclean, J. K.; Jamieson, C. Recent advances inpositive allosteric modulators of the AMPA receptor. Curr. Opin.Drug Discov. Devel., 2006, 9, 571-579.
45. Cordi, A.; Rogers, G. 3-Substituted- [1,2,3]-benzotriazinone com-pound for enhancing glutamatergic synaptic responses. 2008,WO2008085506.
46. Mueller, R.; Lee, S.; O'Hare, S.; Rogers, G.; Rachwal, S.; Street, L. Benzotriazinone derivatives as AMPA receptor enhancers and theirpreparation, pharmaceutical compositions and use in the treatmentof diseases. 2008, WO2008085505.
47. Mueller, R.; Street, L.; Rachwal, S.; Alisala, K. Preparation ofsubstituted triazinone derivatives and analogs as glutamatergic syn-aptic response enhancers. 2009, WO2009038752.
48. Mueller, R.; Street, L. Preparation of benzoxadiazolyl azabicyclylmethanones for enhancing glutamatergic synaptic responses. 2009,WO2009023126.
49. Street, L.; Mueller, R.; Lee, S. Preparation of di-substituted amidesfor enhancing glutamatergic synaptic responses. 2008,WO2008143963.
50. Peters, D.; Christensen, J. K.; Harpsoe, K.; Liljefors, T. Novelquinoxaline derivatives and their preparation, pharmaceutical com-positions and medical use. 2007, WO2007060144.
51. Dominguez-Manzanares, E. AMPA receptor potentiators. 2006,WO2006276532.
52. Andreotti, D.; Arista, L.; Cardullo, F.; Spada, S.; Thewlis, K. M.; Ward, S. E. Preparation of N-arylcyclopropyl isopropylsulfona-mides which potentiate glutamate receptor and uses thereof inmedicine. 2006, WO2006087169.
53. Bradley, D. M.; Thewlis, K. M.; Ward, S. E. Preparation of N-indan-2-yl and related sulfonamides that potentiate glutamate re-ceptor for use against schizophrenia. 2006, WO2006015828.
54. Ward, S. E.; Thewlis, K. M. Preparation of N-indan-2-yl and re-lated sulfonamides that potentiate glutamate receptor for useagainst schizophrenia. 2006, WO2006015829.
55. Thewlis, K. M.; Ward, S. E. Preparation of N-pyrrolidinyl sul-fonamides that potentiate glutamate receptor for use againstschizophrenia. 2006, WO2006015827.
56. Andreotti, D.; Ward, S. E. Preparation of N- [2-phenyltetrahydrofuran-3-yl]-2-propanesulfonamide derivatives asglutamate receptor modulators. 2007, WO2007090841.
57. Thewlis, K. M.; Ward, S. E. Preparation of 4-phenyl-3-(isopropylsulfonylamino)tetrahydrofuran derivatives as glutamatereceptor modulators for treatment of schizophrenia. 2007, WO2007090840.
58. Shepherd T. A.; Aikins J. A.; Bleakman D.; Cantrell B. E.; Rearick J. P.; Simon R. L.; Smith E. C.; Stephenson G. A.; Zimmerman D.M.; Mandelzys A.; Jarvie K. R.; Ho K.; Deverill M.; Kamboj R. K. Design and synthesis of a novel series of 1,2-disubstituted cy-clopentanes as small, potent potentiators of 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA) receptors. J. Med.Chem., 2002, 45, 2101-2111.
59. Thewlis, K. M.; Ward, S. E. Preparation of N-(phenyl-1,3-cyclopentyl) sulfonamides which potentiate the AMPA receptor.2009, WO2009092712.
60. Thewlis, K. M.; Ward, S. E. Preparation of N- [2-(phenylmethyl)cyclopentyl sulfonamides which potentiate theAMPA receptor. 2009, WO2009092713.
61. Bertheleme, N.; Chan, W. N.; Scott, J. S.; Ward, S. E. Preparationof 2-(isopropylsulfonylamino)indane derivatives as potentiators ofAMPA receptors. 2009, WO2009080637.
62. Fernandez M. C.; Castano A.; Dominguez E.; Escribano A.; Jiang D.; Jimenez A.; Hong E.; Hornback W. J.; Nisenbaum E. S.; Rankl N.; Tromiczak E.; Vaught G.; Zarrinmayeh H.; Zimmerman D. M.A novel class of AMPA receptor allosteric modulators. Part 1: de-sign, synthesis, and SAR of 3-aryl-4-cyano-5-substituted-heteroaryl-2-carboxylic acid derivatives. Bioorg. Med. Chem. Lett.,2006, 16, 5057-5061.
63. Zarrinmayeh H.; Tromiczak E.; Zimmerman D. M.; Rankl N.; Ho K. H.; Dominguez E.; Castano A.; Escribano A.; Fernandez C.; Jimenez A.; Hornback W. J.; Nisenbaum E. S. A novel class ofpositive allosteric modulators of AMPA receptors: design, synthe-sis, and structure-activity relationships of 3-biphenyl-4-yl-4-cyano-5-ethyl-1-methyl-1H-pyrrole-2-carboxylic acid, LY2059346.Bioorg. Med. Chem. Lett., 2006, 16, 5203-5206.
64. Magnus N. A.; Staszak M. A.; Udodong U. E.; Wepsiec J. P. Syn-thesis of 4-Cyano pyrroles via Mild Knorr reactions with b-Ketonitriles. Org. Process Res. Dev., 2006, 10, 899-904.
65. Bradley, D. M.; Chan, W. N.; harrison, S.; Hughes, O.; Miller, D.D.; Neesom, J.; Thewlis, K. M.; Ward, S. E. (Arylimino)dihydrothiazoles as AMPA receptor modulators andtheir preparation, pharmaceutical compositions and use in thetreatment of schizophrenia and cognition impairment. 2007, WO2007122241.
66. Chan, W. N.; Harrison, S.; Hughes, O. R.; Neesom, J. K.; Thewlis, K. M.; Ward, S. E. (Phenylimino)thiazole derivatives as AMPA re-ceptor modulators and their preparation, pharmaceutical composi-tions and use in the treatment of schizophrenia. 2009, WO2009053448.
67. Chan, W. N.; Thewlis, K. M.; Ward, S. E. Preparation of (het-ero)aryliminothiazoles as potentiators of AMPA receptors. 2009, WO2009053449.
68. Bertheleme, N.; Bradley, D. M.; Cardullo, F.; Merlo, G.; Pozzan, A.; Scott, J. S.; Thewlis, K. M.; Ward, S. E. Preparation of 1-(2,3-dihydro-1H-inden-5-yl)-1H-pyrazole derivatives as AMPA recep-tor potentiators and their use in medicine. 2008, WO2008113795.
69. Bradley, D. M.; Chan, W. N.; harrison, S.; Thatcher, R.; Thewlis, K. M.; Ward, S. E. Preparation 3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole derivatives and their potential uses as glu-tamate receptor in particular AMPA receptor. 2007, WO2007107539.
70. Bradley, D. M.; Chan, W. N.; Ward, S. E. Preparation of pyra-zolylphenylmethylamines which potentiate AMPA receptor. 2008, WO2008148836.
71. Bradley, D. M.; Thewlis, K. M.; Ward, S. E. Preparation of 4-(fused pyrazolyl) phenylmethylamines which potentiate AMPA re-ceptor. 2008, WO2008148832.
72. Bradley, D. M.; Chan, W. N.; Harrison, S. A.; Thewlis, K. M.; Ward, S. E. Preparation of aryl-substituted 3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazoles which potentiate AMPA receptorand uses thereof in medicine. 2008, WO2008110566.
73. Bradley, D. M.; Chan, W. N.; Thewlis, K. M.; Ward, S. E. Prepara-tion of pyranopyrazoles and pyrazolopyridines as AMPA receptorpotentiators. 2008, WO2008053031.
74. Gallagher, M. G.; Jamieson, C. C.; Lyons, A. J.; Maclean, J. K. F.; Moir, E. M. Heterocyclic derivatives. 2009, WO2009131455.
75. Gillen, K. J.; Jamieson, C.; Maclean, J. K. F.; Moir, E. M.; Rankovic, Z. Preparation of pyrazolealkanamide substituted thio-phenes as AMPA potentiators. 2008, WO2008003452.